Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
IPO Year:
Exchange: NYSE
Website: thermofisher.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/14/2024 | Buy | Redburn Atlantic | |
10/1/2024 | $680.00 | Overweight | Stephens |
8/28/2024 | $670.00 | Overweight | Wells Fargo |
6/3/2024 | $650.00 | Buy | Jefferies |
3/18/2024 | $620.00 | Neutral | Citigroup |
1/24/2024 | $475.00 → $555.00 | Overweight → Equal Weight | Barclays |
1/8/2024 | Outperform → Mkt Perform | Bernstein | |
12/18/2023 | $610.00 | Buy | HSBC Securities |
12/13/2023 | $575.00 | Outperform | Wolfe Research |
10/26/2023 | Overweight → Sector Weight | KeyBanc Capital Markets |
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
Redburn Atlantic initiated coverage of Thermo Fisher with a rating of Buy
Stephens initiated coverage of Thermo Fisher with a rating of Overweight and set a new price target of $680.00
Wells Fargo initiated coverage of Thermo Fisher with a rating of Overweight and set a new price target of $670.00
Jefferies resumed coverage of Thermo Fisher with a rating of Buy and set a new price target of $650.00
Citigroup resumed coverage of Thermo Fisher with a rating of Neutral and set a new price target of $620.00
Barclays downgraded Thermo Fisher from Overweight to Equal Weight and set a new price target of $555.00 from $475.00 previously
Bernstein downgraded Thermo Fisher from Outperform to Mkt Perform
HSBC Securities initiated coverage of Thermo Fisher with a rating of Buy and set a new price target of $610.00
Wolfe Research initiated coverage of Thermo Fisher with a rating of Outperform and set a new price target of $575.00
KeyBanc Capital Markets downgraded Thermo Fisher from Overweight to Sector Weight
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
10-Q - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
144 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
10-Q - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
11-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
SD - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
10-Q - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Highlights Third quarter revenue was $10.60 billion. Third quarter GAAP diluted earnings per share (EPS) was $4.25. Third quarter adjusted EPS was $5.28. Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. To enable the development of advanced materials, we launched the groundbreaking Thermo Scientific Iliad scanning transmission electron microscope, which integrates a number of our advanced technologies into a user-friendly workflow to en
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2024 before the market opens on Wednesday, October 23, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 296868. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2024. Second Quarter 2024 Highlights Second quarter revenue was $10.54 billion. Second quarter GAAP diluted earnings per share (EPS) increased 15% to $4.04. Second quarter adjusted EPS increased 4% to $5.37. Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. This included a number of analytical instruments introduced at the American Society for Mass Spectrometry conference, including the Thermo Scientific™ Stellar™ mass spectrometer, which validates proteins of
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on October 15, 2024, to shareholders of record as of September 13, 2024. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2024 before the market opens on Wednesday, July 24, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 023107. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on July 15, 2024, to shareholders of record as of June 14, 2024. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the developm
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Highlights First quarter revenue was $10.34 billion. First quarter GAAP diluted earnings per share (EPS) increased 4% to $3.46. First quarter adjusted EPS increased 2% to $5.11. Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. This included several analytical instruments: the Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography system, offering higher resolution, faster results, and streamlined workflows for identifying contaminants
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2024 before the market opens on Wednesday, April 24, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 105588. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on April 15, 2024, to shareholders of record as of March 15, 2024. This reflects an 11% increase over the previous dividend payment of $0.35. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in the
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 Highlights Fourth quarter revenue was $10.89 billion, 5% lower versus the same quarter last year. Core organic revenue growth declined 4%. Fourth quarter GAAP diluted EPS was $4.20, 5% higher versus the same quarter last year, driven by 70 basis points of operating margin expansion. Fourth quarter adjusted EPS was $5.67, 5% higher versus the same quarter last year, driven by 100 basis points of adjusted operating margin expansion. Full year revenue was $42.86 billion,
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Highlights Third quarter revenue was $10.60 billion. Third quarter GAAP diluted earnings per share (EPS) was $4.25. Third quarter adjusted EPS was $5.28. Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. To enable the development of advanced materials, we launched the groundbreaking Thermo Scientific Iliad scanning transmission electron microscope, which integrates a number of our advanced technologies into a user-friendly workflow to en
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2024 before the market opens on Wednesday, October 23, 2024, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 296868. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under
Highlights Include the Company's Industry-Leading Businesses, Proven Growth Strategy, and Outstanding Long-Term Financial Outlook Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, hosted its 2024 Investor Day today and provided an in-depth review of the company's proven growth strategy and its industry-leading businesses, which consistently deliver best-in-class products and services that are essential to the work performed by its customers around the world. "We serve very attractive end-markets that are fueled by enduring long-term trends. As an incredibly well-positioned industry leader, we continue to advance scientific discovery through our Mission to enab
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 8:30 a.m. (EDT). You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, so
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2024. Second Quarter 2024 Highlights Second quarter revenue was $10.54 billion. Second quarter GAAP diluted earnings per share (EPS) increased 15% to $4.04. Second quarter adjusted EPS increased 4% to $5.37. Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. This included a number of analytical instruments introduced at the American Society for Mass Spectrometry conference, including the Thermo Scientific™ Stellar™ mass spectrometer, which validates proteins of
New funding will expand CytoReason's disease models and proprietary data, enabling R&D leaders at partner companies to make strategic decisions with greater speed and precision. CytoReason, a leader in developing computational disease models for predictive insights, announced today it secured an aggregated $80 million from OurCrowd, NVIDIA (NASDAQ:NVDA), Pfizer (NYSE:PFE), and Thermo Fisher Scientific (NYSE:TMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240717912688/en/CytoReason is a tech company transforming biopharma's decision-making from trial and error to data-driven, using computational disease models for predicti
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.39 per common share, payable on October 15, 2024, to shareholders of record as of September 13, 2024. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the
myeloMATCH Precision Medicine Clinical Trial Leverages Next-Day Genomic Testing to Quickly Match Patients with Appropriate Trials Across North America To help accelerate research into new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, is partnering with the National Cancer Institute (NCI) – part of the National Institutes of Health – on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. By testing patients' bone marrow and blood for certain genetic biomarkers using Thermo Fisher's next-generation sequencing (NGS) technology, clinical sites
Subsequent Offering Period Scheduled to Expire at 5:00 p.m., New York Time, on July 16, 2024 Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher"), the world leader in serving science, today announced that it has completed its acquisition of Olink Holding AB (publ) ("Olink") (NASDAQ:OLK), a leading provider of next-generation proteomics solutions. The transaction values Olink at approximately $3.1 billion, net of $96 million of acquired cash. Olink will become part of Thermo Fisher's Life Sciences Solutions segment. "We are excited to welcome Olink colleagues to Thermo Fisher," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. "Protein research
UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced that the UK Competition and Markets Authority (the "CMA") has unconditionally approved the previously announced tender offer (the "Offer") by Orion Acquisition AB (the "Buyer"), a wholly owned subsidiary of Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher" or "Parent"), for all outstanding Common Shares and American Depositary Shares (together, the "Shares") of Olink for $26.00 per Share. The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink. As a result of the CMA approval, Olink and Thermo Fis
Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4
Traci Kyes and Makis Sigalas bring extensive industry experience to roles focused on expanding ViroCell's business in the US and Europe Team ViroCell will be attending the Cell & Gene Therapy Meeting on the Mesa, 10-12 October 2023 ViroCell Biologics ("ViroCell" or the "Company"), a specialist contract development and manufacturing organisation ("CDMO") in cell and gene therapy clinical trials, announces the appointment of Traci Kyes as Vice President (VP) of Business Development (US) and Makis Sigalas as Senior Business Development Director (Europe). Focused on driving growth in the US and Europe, respectively, Traci and Makis bring a wealth of business development expertise to ViroCel
FORT LAUDERDALE, Fla. and Sacramento, Calif., March 16, 2023 /PRNewswire/ -- Gemini BioProducts Holding, Inc. ("GeminiBio" or the "Company"), a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, announced the appointment of Cory Stevenson as Executive Chairman of the Board of Directors. GeminiBio Appoints Industry Veteran Cory Stevenson as Executive ChairmanMr. Stevenson joined the Board of GeminiBio in 2022 and has been working closely with the GeminiBio management team as they prepare to complete a three-pha
Life sciences tools veteran brings decades of experience leading successful teams, commercializing industry-defining technology platforms, and scaling global organizations Resolve Biosciences, a company pioneering Molecular Cartography™ technology, announced today that it has appointed John Stark as Chief Executive Officer. As part of this transition, Resolve Biosciences' previous CEO, Jason Gammack, will be leaving the company. Mr. Stark brings more than 20 years of experience commercializing early-stage technologies, scaling organizations, and navigating capital markets for some of the most innovative life sciences companies. Most recently, Mr. Stark was Chief Executive Officer of Quant
* Cory Stevenson, former President of the BioProduction divisionat Thermo Fisher Scientific joins Board FORT LAUDERDALE, Fla and SACRAMENTO, Calif., Sept. 14, 2022 /PRNewswire/ -- Gemini BioProducts Holding, Inc. ("GeminiBio" or the "Company"), a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, announced the appointment of Cory Stevenson to its Board of Directors. Gemini BioProducts Holding, Inc. announces the appointment of Cory Stevenson, to its Board of Directors.Mr. Stevenson retired in 2021 from Thermo Fisher Scientific (NYSE:TMO), where he served as the President of the BioProduction Division. Thermo Fisher Scientif
Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced the appointment of experienced biotechnology executive, Dawn Mattoon, PhD, as Chief Operating Officer, effective today. In her nearly 20-year career, Dr. Mattoon has developed and commercialized a broad range of innovative proteomic and genomic technologies. Dr. Mattoon possesses a proven track record of delivering top and bottom-line growth as a leader in research and development, strategy, and general management for companies such as Invitrogen, Life Technologies, Thermo Fisher Scientific Inc. (NYSE:TMO), and Cell Signaling Technologies. Most recently, Dr.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird increased Apple Inc. (NASDAQ:AAPL) price target from $200 to $240. Baird analyst William Power maintained an Outperform rating. Apple shares fell 0.1% to trade at $218.51 on Thursday. See how other analysts view this stock. Truist Securities raised the price target for ServiceNow, Inc. (NYSE:NOW) from $750 to $780. Truist Securities analyst Joel Fishbein maintained a Hold rating. ServiceNow shares gained 11.9% to trade at $817.75 on Thursday. See how other analysts view this stock. JP Morg
Stifel analyst Daniel Arias maintains Thermo Fisher Scientific (NYSE:TMO) with a Buy and raises the price target from $600 to $615.
Thermo Fisher Scientific (NYSE:TMO) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 1 0 0 2M Ago 1 0 0 0 0 3M Ago 1 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $630.4, a high estimate of $670.00, and a low estimate of $600.00. This upward trend is apparent, with t
Baird analyst Catherine Schulte maintains Thermo Fisher Scientific (NYSE:TMO) with a Outperform and raises the price target from $620 to $632.
Wall Street experienced a turbulent session on Wednesday, with the S&P 500 index heading toward its worst performance in over a year and the tech-focused Nasdaq 100 eyeing its fifth decline in the last six sessions. The Magnificent Seven group — Microsoft Corp. (NYSE:MSFT), Apple Inc. (NASDAQ:AAPL), NVIDIA Corp., Alphabet Inc., Amazon Inc. (NASDAQ:AMZN), Meta Platforms Inc. (NASDAQ:META) and Tesla, Inc. — wiped out over $570 billion in their combined market valuation by midday trading in New York. The Roundhill Magnificent Seven ETF (NYSE:MAGS) fell 4.9%, marking the worst daily performance since the fund’s inception last year. Tesla shares plummeted over 11% after missing earnings exp
On Wednesday, Thermo Fisher Scientific Inc. (NYSE: TMO) posted a second-quarter revenue of $10.54 billion, down 1% year-over-year, beating the consensus of $10.51 billion. Organic revenue was 1% lower, and Core organic revenue growth was flat. Revenue from the Life Sciences Solutions Segment declined by 4.4% to $2.36 billion. Analytical Instruments Segment sales were up 1.9% to $1.78 billion. Specialty Diagnostics Segment revenues were almost flat at $1.12 billion, and Laboratory Products and Biopharma Services segment sales were down 1.3% to $5.76 billion. Adjusted EPS of $5.37 beat the consensus of $5.12 and grew from $5.15 a year ago. Adjusted operating margin was almost unch
Wall Street is gearing up for a negative start on Thursday, as traders mull over earnings from Tesla, Inc. (NASDAQ:TSLA) and Alphabet, Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG), which incidentally haven’t been received well by the Street. While Tesla’s earnings were dismissed as of low quality, investors worried about Alphabet’s massive capex boost as it eyes supremacy in the AI market. The market may also focus on private sector activity readings due shortly after the market opens. “Mega tech has an unprecedented influence on market moves and overall earnings,” fund manager Louis Navellier said in a note. Traders may choose to remain on the sidelines until they get more clarity on the earnings f